Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Kenvue Inc.

Rank #186ValueWatchlistCompare with other stocks

KVUE · NYSE · Consumer Defensive

Kenvue Inc. (KVUE) — Rank #186 by gross profitability (GP/assets 0.33) · ROE 13.9% · Piotroski F-Score N/A.

As-of 2026-10-30 · CIK 0001944048 · all metrics point-in-time as of the filing date.

About

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.

Show more

It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.

was incorporated in 2022 and is headquartered in Summit, New Jersey.

Industry
Household & Personal Products
Sector
Consumer Defensive
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
January 3
Website
kenvue.com

Company Snapshot

P/E and dividend yield are the primary valuation lenses for mature businesses.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

21,780

Industry

Household & Personal Products

Exchange

NYSE

11/12

Flags passed

KVUE fails 1 critical flag

Passes 11 of 12 quality flags

  • FAIL
    Revenue declining YoY

    Revenue contracted year over year

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Operating leverage expanding · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.33
Return on equity
13.9%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.53
Current ratio
1.01×
Net cash
-$296.00M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
0.9%

Growth

1/2 pass
Revenue growth
-2.1%
Piotroski F-Score
N/A
Share dilution
0.1%

Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).

Profitability

Does it make money well?

Warning: Revenue declining YoY · GP/assets 68th percentile of 39 SIC 28 peers

Gross profitability (GP / assets)

0.33

Primary signal (Novy-Marx).

68th pctl of 39 SIC 28 peers

Return on equity

13.9%

Gross margin

58.1%

63rd pctl of 39 SIC 28 peers

Revenue growth (YoY)

-2.1%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2023202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

0.4%

Revenue CAGR (5Y)

—

Earnings CAGR (3Y)

-10.7%

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 17% above net income

Free cash flow

$1.72B

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

17.1%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

0.9%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net debt $296.00M

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.53

3rd pctl of 35 SIC 28 peers (best = lowest)

Current ratio

1.01×

0th pctl of 39 SIC 28 peers

Quick ratio

0.61×

Net cash

-$296.00M

Cash & equivalents minus total debt.

Piotroski F-Score

N/A

Only 8/9 components determinable.

Valuation

Is the price reasonable?

No warning flags

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

24.7xExpensive
15.6xmed 20.9x43.2x

P / S

Price / revenue per share

2.4xExpensive
2.1xmed 2.3x2.9x

P / B

Price / book value per share

3.4xExpensive
1.6xmed 3.1x4.6x

P / GP

Price / gross profit per share

4.1xExpensive
3.8xmed 4.0x5.0x

P / FCF

Price / free cash flow per share

20.9xFair
12.9xmed 20.9x828.2x

Dividend safety

Composite score

1.0 / 5

Weak
Payout ratio
107.6%0/5 Weak
FCF coverage
1.09×2/5 Fair
Dividend growth streak
2 yr1/5 Weak
Balance-sheet health
D/E 1.53 · IC N/A1/5 Weak

Capital allocation quality

Composite score

2.0 / 5

Fair
Share count trend
0.1%2/5 Fair
Buyback timing
vs own P/E history0/5 Weak
Dividend growth consistency
2 yr1/5 Weak
Net debt trajectory(deleveraging)
26.0%5/5 Strong

Lifecycle Phase History

20222025
Capital Return
Value

Price History

KVUE-24.3% · -7.9% CAGRSPY+97.8% · +22.3% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports